載入...
Intracavitary chemotherapy with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is not superior to TKI monotherapy in controlling malignant pleural effusion recurrence in EGFR-mutated lung cancer patients
BACKGROUND: Epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC) patients benefit from EGFR-tyrosine kinase inhibitors (TKIs) therapy. There are few studies comparing the efficacy between intrapleural chemotherapy combination with TKIs and TKIs alone in controlling re-a...
Na minha lista:
| 發表在: | J Thorac Dis |
|---|---|
| Main Authors: | , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
AME Publishing Company
2019
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6790470/ https://ncbi.nlm.nih.gov/pubmed/31656643 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jtd.2019.09.36 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|